Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). complete remission rates are close to 60% to 70%. and relapses occur in >40% of cases. Here. https://stilleners.shop/product-category/style/